Embedding GDPR compliance into a data-driven research platform

Background

When 3 Billion Pairs Genetic (3BP) engaged with us, they were operating at the intersection of epigenomics, machine learning, and large-scale data analysis. Their work required collaboration with pharmaceutical manufacturers, medical associations, and global health bodies, each with stringent expectations around data protection.

As a data controller handling sensitive personal data, 3BP needed to demonstrate a clear and defensible approach to GDPR compliance. This was not only a regulatory requirement but a prerequisite for securing and maintaining partnerships within the life sciences sector.

The LS Law Approach

We approached the engagement by positioning data protection as an operational framework rather than a standalone compliance exercise. Our objective was to provide 3BP with clarity on their legal obligations and embed processes that could support both current activities and future growth.

We began by advising on their role and responsibilities as a data controller under GDPR. This included addressing areas of uncertainty and translating regulatory requirements into practical steps aligned with their research and commercial objectives.

We then worked with 3BP to establish a data privacy by design roadmap. This ensured that data protection considerations were incorporated into their systems and processes from the outset, rather than applied retrospectively.

A key component of our work was the design of a structured Data Protection Impact Assessment (DPIA) process. This provided a consistent method for identifying, assessing, and mitigating data protection risks, particularly important given the sensitivity and scale of the data involved.

Throughout the process, we maintained close collaboration with the 3BP team, ensuring that legal guidance was actionable and integrated into their day-to-day operations.

The Outcome

3BP achieved a robust and demonstrable level of GDPR compliance, enabling them to operate with greater certainty in a highly regulated environment.

Their approach to data protection became systematic rather than reactive, with clear processes in place to assess and manage risk. This strengthened their ability to protect individual data and provided assurance to external partners.

As a result, 3BP was able to engage confidently with pharmaceutical and life sciences organisations, meeting the data governance standards required for collaboration. The DPIA framework continues to support ongoing compliance as their work evolves.